Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drop showdown: could common glaucoma meds save more than sight?

NCT ID NCT07074782

Knowledge-focused Sponsor: Association for Innovation and Biomedical Research on Light and Image Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a common type of glaucoma eye drop (prostaglandin analogues) can protect the eye's nerve cells directly, not just by lowering eye pressure. Researchers will review medical records from 1500 adults with glaucoma over 3 years, comparing those on prostaglandin drops to those on other pressure-lowering drops. The goal is to see if one type offers better long-term nerve protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1500 eyes (750 treated with prostaglandin analogues and 750 treated with a different IOP-lowering compound)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18+ years * Established glaucoma diagnosis (primary open-angle glaucoma, normal tension Glaucoma, pseudoexfoliation glaucoma, pigmentary dispersion glaucoma) in either eye * Visual field mean deviation (MD; location-weighted mean difference from average age-corrected visual field sensitivity) of 2 visual fields differing by no more than 3 dB, for a mean deviation of better than -6.0 dB, or by no more than 4 dB, for a mean deviation worse than -6.0 dB, as measured using Humphrey perimetry (or equivalent Haag-Streit / Octopus; in at least one eye; analogous to The United Kingdom Glaucoma Treatment Study) * Treatment with either prostaglandin analogues only or another topically applied IOP-lowering compound only for at least 3 years * Documented follow-up period of at least 3 years * At least 6 patient visits documented over the follow-up period with readings of IOP, visual field, OCT * No additional glaucoma intervention apart from laser trabeculoplasty and/or cataract surgery during the observational period Exclusion Criteria: * Follow-up period \< 3 years * Number of patient visits \<6 visits * Number of OCT, visual field readings during the observation period \< 6 * Low compliance/therapy interruption * Beginning of combination therapy of prostaglandin analogues and other IOP lowering eye drops during the observation period * In case of glaucoma diagnosis in both eyes: different topical IOP-lowering treatment regimes (e.g. prostaglandin analogues in one eye and beta-adrenergic blocking agents in the fellow eye) * Additional glaucoma intervention during the observational period other than laser trabeculoplasty and/or cataract surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome glaucoma low tension glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre for Clinical Trials at San Paolo Hospital University of Milan

    Milan, Italy

  • Centro de Oftalmologia Barraquer

    Barcelona, Spain

  • Clinical Eye Research Centre - St. Paul's Eye Unit, Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • Department of Ophthalmology University of Bonn

    Bonn, Germany

  • Eye Unit, University Hospital Maggiore della Carità

    Novara, Italy

  • ICORG - Imperial College Ophthalmologic Research Group

    London, United Kingdom

  • NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust

    London, United Kingdom

  • Retina Unit, Department of Ophthalmology, Bellvitge University Hospital

    Barcelona, Spain

  • University Eye Hospital Leipzig

    Leipzig, Germany

  • University Hospital Basel

    Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.